Introduction: Oral iron as a supplement has been associated with adverse health consequences, especially in the context of young children with active malaria. A potential aggravating role of non-transferrin-bound iron (NTBI) has been proposed. Material and Methods: NTBI responses in both a fasting and post-oral iron dosing situation were related to serum iron concentration and ferritin status. Fasting and 1, 2, and 3 h postdose serum samples were obtained in conjunction with oral ferrous sulfate supplementation in aqueous solution of 0, 15, 30, 60, 120 and 240 mg Fe in a cohort of 8 healthy Guatemalan men over a 9-week metabolic protocol. Hemoglobin, serum ferritin, percent transferrin saturation, serum iron and NTBI were all measured. Results: Circulating levels of serum iron and NTBI increased in a graded fashion in response to oral iron, with the relative increment for NTBI slightly greater than that of iron. Detectable NTBI was occasionally measured in fasting specimens, more frequently in subjects with high ferritin status. Post-iron NTBI responses, by contrast, were higher in normal-ferritin subjects in absolute terms, and rose with increasing postabsorptive serum iron responses. Discussion: The appearance and response of circulating NTBI were consistent with recognized principles of iron regulation.

Keywords:
Iron status, Serum iron, Non-transferrin-bound iron, Ferritin, Iron absorption, Guatemala
1.
Hershko C, Graham G, Bates GW, Rachmilewitz EA: Non-specific serum iron in thalassaemia: an abnormal serum iron fraction of potential toxicity. Br J Haematol 1978;40:255–269.
2.
Chrichton R: Transferrin iron binding and release; in Crichton R (ed): Inorganic Biochemistry of Iron Metabolism. Chichester, Willey, 2001, pp 111–114.
3.
Jacobs WMG, Hendriks JCM, van Tits BLJH, et al: Results of an international round robin for the quantification of serum non-transferrin-bond iron: need for defining standardization and a clinically relevant isoform. Anal Biochem 2005;341:241–250.
4.
Simpson RJ, Cooper CE, Raja KB, et al: Non-transferrin-bound iron species in the serum of hypotransferrinaemic mice. Biochim Biophys Acta 1992;1156:19–26.
5.
Breuer W, Hershko C, Cabantchik ZI: The importance of non-transferrin-bound iron in disorders of iron metabolism. Transfus Sci 2000;23:185–192.
6.
Esposito BP, Breuer W, Sirinkarpracha P, et al: Labile plasma iron in iron overload: redox activity and susceptibility to chelation. Blood 2003;102:2670–2677.
7.
LeLan C, Loreal O, Cohen T, et al: Redox active plasma iron in C282Y/C282Y hemochromatosis. Blood 2005;105:4527–4531.
8.
deValk B, Addicks MA, Gosriwatana I, et al: Non-transferrin-bound iron is present in serum of hereditary haemochromatosis heterozygotes. Eur J Clin Invest 2000;30:248–251.
9.
Hutchison C, Al-Ashgar W, Liu DY, et al: Oral ferrous sulphate leads to a marked increase in pro-oxidant nontransferrin-bound iron. Eur J Clin Invest 2004;34:782–784.
10.
Dresow B, Petersen D, Fischer R, Nielsen P: Non-transferrin-bound iron in plasma followed administration of oral iron drugs. Biometals 2008;21:273–276.
11.
Kiechel S, Willeit J, Egger G, Poewe W, Oberhollenzer F: Body iron stores and the risk of carotide atherosclerosis: prospective results from the Bruneck study. Circulation 1997;96:3300–3307.
12.
Darlea Usmar V, Halliwell B: Blood radicals: reactive nitrogen species, reactive oxygen species, transition metal ions, and the vascular system. Pharm Res 1996;13:649–662.
13.
Patruta SI, Edlinger R, Sunder-Plassmann G, Hörl WH: Neutrophil impairment associated with iron therapy in hemodialysis patients with functional iron deficiency. J Am Soc Nephrol 1998;9:655–663.
14.
Barton Pai A, Pai MP, Depczynski J, McQuade CR, Mercier RC: Non-transferrin-bound iron is associated with enhanced Staphylococcus aureus growth in haemodialysed patients receiving intravenous iron sucrose. Am J Nephrol 2006;26:304–309.
15.
Canziani ME, Yumiya ST, Rangel EB, et al: Risk of bacterial infection in patients under intravenous iron therapy: doses versus length of treatment. Artif Organs 2001;25:866–869.
16.
Gray C, McCormick C, Turner G, Craig A: ICAM-1 can play a major role in mediating P. falciparum adhesion to endothelium under flow. Mol Biochem Parasitol 2003;128:187–193.
17.
Kartikasari AER, Georgiou NA, Visserer FLJ, et al: Endothelial activation and induction of monocyte adhesion by non-transferrin-bound iron present in human sera. FASEB J 2005;20:353–355.
18.
Matinaho S, Karkumäki P, Parkkinen J: Bicarbonate inhibits the growth of Staphylococcus epidermidis in platelet concentrates by lowering the level of non-transferrin-bound iron. Transfusion 2005;45:1768–1773.
19.
McLean E, Egli I, Cogswell M, de Benoist B, Wijdla D: Worldwide prevalence of anemia in preschool aged children, pregnant women and non-pregnant women of reproductive age; in Kraemer K, Zimmerman T (eds): Nutritional Anemia. Basel, Sight & Life Press, 2007, pp 1–12.
20.
Stolzfus RJ, Dreyfuss ML: Guidelines for the Use of Iron Supplements to Prevent and Treat Iron Deficiency Anemia. Washington, ILSI Press, 1998.
21.
Sazawal S, Black RE, Ramsan M, et al: Effects of routine prophylactic supplementation with iron and folic acid on admission to hospital and mortality in preschool children in a high malaria transmission setting: community-based, randomised, placebo-controlled trial. Lancet 2006;367:133–143.
22.
English M, Snow RW: Iron and folic acid supplementation and malaria risk. Lancet 2006;367:90–91.
23.
Bothwell TH, Charlton RW, Cook JD, Finch CA: Plasma iron; in Bothwell TH, Charlton RW, Cook JD, Finch CA (eds): Iron Metabolism in Men. Oxford, Blackwell Scientific Publications, 1979, pp 284–310.
24.
Breuer W, Cabantchik ZI: A fluorescence-based one-step assay for serum non-transferrin-bound iron. Anal Biochem 2001;299:194–202.
25.
Ekenved G, Norrby A, Sölvell L: Serum iron increase as a measure of iron absorption – studies on the correlation with total absorption. Scand J Haematol Suppl 1976;28:31–49.
26.
Ekenved G: Absorption from different types of iron tablets – correlation between serum iron increase and total absorption of iron. Scand J Haematol Suppl 1976;28:51–63.
27.
Schächner E, Ronen M, Pinklaus J, Djaldetti M: Iron absorption in patients with polycythemia vera: a comparative study using the whole-body counter and the ferrous sulfate absorption text. Eur J Nucl Med 1978;3:125–127.
28.
Heinrich HC, Fischer R: Correlation of postabsorptive serum iron increase and erythrocyte-59Fe-incorporation with the whole body retention of absorbed 59Fe. Klin Wochenschr 1982;60:1493–1496.
29.
Hoppe M, Hulthen L, Hallberg L: The validation of using serum iron increase to measure iron absorption in subjects. Br J Nutr 2004;92:485–488.
30.
Kaltwasser JP, Schwarz-van de Sand W: Orale Eisentherapie: Bioverfügbarkeit und therapeutische Wirksamkeit von Ferro-Eisen als Brausetabletten bei posthämorrhagischer Eisenmangelanämie. Dtsch Med Wochenschr 1989;114:1188–1195.
31.
Dirren H, Logman MH, Barclay DV, Freire WB: Altitude correction for hemoglobin. Eur J Clin Nutr 1994;48:625–632.
32.
Bothwell TH, Charlton RW, Cook JD, Finch CA: Iron absorption; in Bothwell TH, Charlton RW, Cook JD, Finch CA (eds): Iron Metabolism in Man. Oxford, Blackwell, 1979, pp 256–283.
33.
Beard JL, Dawson H, Pinero DJ: Iron metabolism: a comprehensive review. Nutr Rev 1996;54:295–317.
34.
Beard J: Iron; in Bowman BA, Russell RM (eds): Present Knowledge in Nutrition, ed 9. Washington, ILSI Press, 2007, pp 445–457.
35.
de Benoist B, Fontaine O: Summary of the Conclusions of the WHO Consultation on Prevention and Control of Iron Deficiency in Infants and Young Children in Malaria Endemic Areas. Lyon, World Health Organization, 2007.
36.
Schümann K, Ettle T, Szegner B, Elsenhans B, Solomons NW: On risks and benefits of iron supplementation recommendations for iron intake revisited. J Trace Elem Med Biol 2007;21:147–168.
37.
Slotkin S, Tondeur M: Successful approaches: sprinkles; in Kraemer K, Zimmerman T (eds): Nutritional Anemia. Basel, Sight & Life Press, 2007, pp 269–284.
38.
Centers for Disease Control and Prevention. Recommendations to prevent and control iron deficiency in the United States. MMWR Recomm Rep 1998;47:1–29.
39.
Pena-Rosas JP, Nesheim MC, Garcia-Casal MN, et al: Intermittent iron supplementation regimens are able to maintain safe maternal hemoglobin concentrations during pregnancy in Venezuela. J Nutr 2004;134:1099–1104.
40.
Solomons NW, Schümann K: Safety of interventions; in Kraemer K, Zimmerman M (eds): Nutritional Anemia. Basel, Sight & Life Press, 2007, pp 285–314.
41.
Hider RC: Nature of non-transferrin-bound iron. Eur J Clin Nutr 2002;32(suppl I):50–54.
42.
Sahlstedt L, Ebeling F, von Bansdarf L, Parkinen J, Ruutu T: Non-transferrin-bound iron during allogenic stem cell transplantation. Br J Haematol 2001;113:836–838.
43.
Ettle T, Elsenhans B, Windisch W, Srai SKS, Schümann K: Mobilisation of recently absorbed 59Fe in ex vivo perfused rat duodena and the influence of iron status and subsequently absorbed chelators. J Trace Elem Med Biol 2006;19:231–241.
44.
Martell AE, Smith RM: Critical Stability Constants. New York, Plenum Press, 1974.
45.
Bates GW, Billups C, Saltman P: The kinetics and mechanism of Fe(III) exchange between chelates and transferrin. I. The complexes of citrate and nitrilotriacetic acid. J Biol Chem 1967;242:2810–2815.
46.
Bates GW, Billups C, Saltman P: The kinetics and mechanism of Fe(III) exchange between chelates and transferrin. II. The presentation and removal with ethylenediaminetetracetate. J Biol Chem 1967;242:2816–2821.
47.
Muta K, Nishimura J, Ideguchi H, Umemura T, Ibayashi H: Erythroblast transferrin receptors and transferrin kinetics in iron deficiency and various anemias. Am J Hematol 1987;25:155–163.
48.
Schümann K, Szegner B, Kohler B, Pfaffl M, Ettle T: A method to assess 59Fe in residual tissue blood content in mice and its use to correct 59Fe-distribution kinetics accordingly. Toxicology 2007;241:19–32.
© 2012 S. Karger AG, Basel
2012
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.